Using heat therapy to treat warts in special populations
Multicenter Real-World Study of Hyperthermia in Skin/Mucosal HPV Infection of Special Population
This study is testing if heat therapy can safely help treat warts in special groups like pregnant women, children, and people with autoimmune diseases or HIV.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Sex | All |
| Sponsor | First Hospital of China Medical University Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06827938 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of local hyperthermia, specifically using an infrared thermotherapy apparatus, to treat viral warts in various special populations, including pregnant women, children, and patients with autoimmune diseases or HIV. The approach aims to mobilize the body's immune response to eliminate HPV infections, with previous research indicating a cure rate of 45-55%. The study is designed to assess the safety and efficacy of this method compared to traditional treatments, which often have higher recurrence rates and more trauma.
Who should consider this trial
Good fit: Ideal candidates include pregnant women, children, and patients with autoimmune diseases or HIV who have viral warts.
Not a fit: Patients with tumors or other serious diseases that prevent them from completing the study will not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could provide a non-invasive and effective option for patients suffering from viral warts.
How similar studies have performed: Previous studies have shown promising results with hyperthermia for treating viral warts, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pregnant women with viral warts 2. Diagnosis of AIDS with viral warts 3. Autoimmune disease patients with viral warts 4. Diabetic patients with viral warts 5. Patients with viral warts who are currently being treated with immunosuppressants 6. Children with viral warts 7. The subject or legal guardian is able to understand and sign the informed consent/consent to participate in the study Exclusion Criteria: 1. The subject suffers from tumor or other serious disease and cannot complete this clinical study 2. Timely treatment and follow-up cannot be guaranteed due to personal or other objective reasons
Where this trial is running
Shenyang, Liaoning
- The First Affiliated Hospital of China Medical University — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Study coordinator: Wei Huo, Doctor
- Email: huozhongfang@163.com
- Phone: 024-83282524
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.